3-(2,4-二氯苯基)-1-丙醇 | 146882-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2,4-二氯苯基)-1-丙醇
• 英文名称: 3-(2,4-dichlorophenyl)propan-1-ol
• CAS: 146882-07-7
• 化学式: C₉H₁₀Cl₂O
• 分子量: 205.084
• InChiKey: NUNJMARRFKAAIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(2,4-二氯苯基)-1-丙醇 在 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.59h， 生成 Methyl 4-[3-(2,4-dichlorophenyl)propylsulfanyl]-3-oxobutanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  3-(2,4-二氯苯基)-2-丙烯-1-醇 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(2,4-二氯苯基)-1-丙醇
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• [EN] SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS<br/>[FR] DERIVES DU THIOPHENE SUBSTITUES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：CHIRON CORP

  公开号：WO2005095386A1

  公开（公告）日：2005-10-13

  The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula (I).

  本发明涉及新的取代五元化合物及其药用盐、酯或前药，新化合物与药用载体的组合物，以及新化合物的用途。本发明的化合物具有以下一般式（I）。
• Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists
  作者：Miguel Guerrero、Mariangela Urbano、Jian Zhao、Melissa Crisp、Peter Chase、Peter Hodder、Marie-Therese Schaeffer、Steven Brown、Hugh Rosen、Edward Roberts

  DOI：10.1016/j.bmcl.2011.10.096

  日期：2012.1

  potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure–activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1–3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility

  S1P 4受体 (S1P 4 -R) 的高亲和力和选择性小分子激动剂可能在包括自身免疫性疾病、病毒感染和血小板减少症在内的多种疾病领域具有重要的治疗效用。分子库-小分子库库的高通量筛选 (HTS) 鉴定出 3-(2-(2,4-dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine 是一种中等效力和选择性的 S1P 4 -R击中激动剂。HTS 衍生命中的设计、合成和系统的结构-活性关系研究导致了新型强效 S1P 4 -R 激动剂的开发，该激动剂对剩余的 S1P 1-3,5 具有极好的选择性-Rs 家庭成员。值得注意的是，本文报道的分子提供了新的药理学工具来破译生物学功能并评估 S1P 4 -R的治疗效用。
• Substituted 2,5-heterocyclic derivatives
  申请人：Jefferson B. Anne

  公开号：US20050256121A1

  公开（公告）日：2005-11-17

  The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的取代的五元化合物及其药学上可接受的盐、酯或前药，以及新化合物与药学上可接受的载体的组合物，以及新化合物的用途。该发明的化合物具有以下一般式：
• Imidazo[1,2,-A]pyridine ether compounds as ion channel modulators
  申请人：——

  公开号：US20040048885A1

  公开（公告）日：2004-03-11

  Imidazo[1,2-&agr;]pyridine ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment or prevention of atrial or ventricular arrhythmia as well as atrial or ventricular fibrillation.

  本发明披露了咪唑[1,2-a]吡啶醚类化合物。本发明的化合物可纳入组合物和套件中。本发明还披露了化合物和组合物的多种体外和体内用途，包括治疗或预防心房或心室心律失常以及心房或心室颤动。
• SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES
  申请人：Lin Xiaodong

  公开号：US20080255120A1

  公开（公告）日：2008-10-16

  The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的取代五元化合物及其药学上可接受的盐、酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。本发明的化合物具有以下一般式：